Outbreak of Cryptosporidium hominis in northern Sweden: persisting symptoms in a five-year follow-up

preprint OA: closed CC-BY-4.0
📄 Open PDF Full text JSON View at publisher
AI-generated summary by claude@2026-07, 2026-07-15

Infected individuals from a 2010-2011 Cryptosporidium hominis outbreak reported significantly more gastrointestinal and joint-related symptoms five years later compared to uninfected individuals.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-07, 2026-07-15 · read from full text

This prospective cohort study followed inhabitants of Östersund, Sweden, five years after a large 2010–2011 waterborne Cryptosporidium hominis outbreak, comparing self-reported post-infectious symptoms between individuals classified as infected “cases” and “non-cases.” Using a mailed symptom questionnaire (with parent/guardian completion for children) and logistic regression adjusted for age and sex, the study found that infected individuals were more likely than uninfected individuals to report multiple gastrointestinal and joint-related symptoms at follow-up, including watery diarrhoea, diarrhoea, abdominal pain, bloating, acid indigestion, altered bowel habits, swollen joints/joint pain, ocular pain, nausea, and fatigue. Overall, 56.5% of cases reported symptoms versus 41.2% of non-cases, and the associations varied by age group. The study’s key limitation is that symptom outcomes were based on self-report questionnaires without an external clinical confirmation of causes. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract ObjectivesIn 2010-2011, a waterborne outbreak of the parasite, Cryptosporidium hominis, affected approximately 27,000 inhabitants in the city of Östersund, Sweden. Previous research suggested that post-infectious symptoms, such as gastrointestinal symptoms and joint pain, could persist for up to two years after the initial infection. In this study, we investigated whether the parasite caused post-infectious sequelae for up to five years after the outbreak. This prospective cohort study examined whether individuals infected during the outbreak were more likely than uninfected individuals to report post-infectious symptoms five years later. The participants completed a questionnaire on whether they experienced a list of symptoms. We analysed data using logistic regression and calculated odds ratios with 95% confidence intervals.Results The analysis included 626 individuals. Among the 262 individuals infected during the outbreak, 56.5% reported symptoms at follow-up. Compared to uninfected individuals, infected individuals were significantly more likely to report watery diarrhoea, diarrhoea, swollen joints, abdominal pain, bloating, joint discomfort, acid indigestion, alternating bowel habits, joint pain, ocular pain, nausea, and fatigue at the follow-up, after adjusting for age and sex. Our findings suggested that cryptosporidiosis was mainly associated with gastrointestinal- and joint-related post-infectious symptoms for up to 5 years after the infection.
Full text 89,172 characters · extracted from preprint-html · click to expand
Outbreak of Cryptosporidium hominis in northern Sweden: persisting symptoms in a five-year follow-up | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research note Outbreak of Cryptosporidium hominis in northern Sweden: persisting symptoms in a five-year follow-up Malin Sjöström, Malin Arvidsson, Lars Söderström, Mikael Lilja, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-742939/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 9 You are reading this latest preprint version Abstract Objectives In 2010-2011, a waterborne outbreak of the parasite, Cryptosporidium hominis , affected approximately 27,000 inhabitants in the city of Östersund, Sweden. Previous research suggested that post-infectious symptoms, such as gastrointestinal symptoms and joint pain, could persist for up to two years after the initial infection. In this study, we investigated whether the parasite caused post-infectious sequelae for up to five years after the outbreak. This prospective cohort study examined whether individuals infected during the outbreak were more likely than uninfected individuals to report post-infectious symptoms five years later. The participants completed a questionnaire on whether they experienced a list of symptoms. We analysed data using logistic regression and calculated odds ratios with 95% confidence intervals. Results The analysis included 626 individuals. Among the 262 individuals infected during the outbreak, 56.5% reported symptoms at follow-up. Compared to uninfected individuals, infected individuals were significantly more likely to report watery diarrhoea, diarrhoea, swollen joints, abdominal pain, bloating, joint discomfort, acid indigestion, alternating bowel habits, joint pain, ocular pain, nausea, and fatigue at the follow-up, after adjusting for age and sex. Our findings suggested that cryptosporidiosis was mainly associated with gastrointestinal- and joint-related post-infectious symptoms for up to 5 years after the infection. General Biochemistry Molecular Genetics Molecular Biology Cryptosporidium sequelae diarrhea post-infectious symptoms Figures Figure 1 Introduction Cryptosporidium is a protozoan parasite that can infect humans and animals. More than 20 species have been identified, but C. hominis and C. parvum c ause the majority of infections in humans [ 1 , 2 ]. Cryptosporidium is mainly transmitted through the faecal-oral route, either through oocyst-contaminated water or food or through direct contact with an infected person or animal [ 3 ]. Cryptosporidiosis occurs worldwide and in all age groups [ 3 ]. Many small waterborne outbreaks have been reported globally, but only a few large outbreaks have been reported [ 4 ]. To date, the largest outbreak occurred in Milwaukee, Wisconsin, in 1993. In that outbreak, 400,000 people were infected through the public water supply [ 5 ]. In November 2010, Östersund, a city in northern Sweden, experienced a large outbreak of acute diarrhoea, caused by C. hominis IbA10G2, which was transmitted through the public water supply. Approximately 27,000 (45%) of 59,000 inhabitants reported symptoms compatible with cryptosporidiosis [ 6 ]. The most common symptoms of cryptosporidiosis are watery diarrhoea, nausea, vomiting, fever, and abdominal pain. The symptoms typically last a few days to 2–3 weeks [ 3 ], but the infection can also be asymptomatic. [ 2 ] Children, particularly those < 2 years old, often display more severe symptoms than adults [ 7 ]. Post-infectious symptoms after cryptosporidiosis have been described in several studies [ 8 – 10 ]. Long-term sequelae are common after C. hominis infections, including diarrhoea, abdominal pain, nausea, fatigue, and headache [ 11 ]. Among children in developing countries, cryptosporidiosis has been associated with increased mortality (12), impaired physical fitness, and impaired cognitive function [ 13 ]. Two years after the outbreak in Östersund, individuals that had been infected during the outbreak (cases) were more likely than those that had not been infected (non-cases) to report gastrointestinal symptoms, fatigue, headache, or joint-related symptoms [ 14 ]. Although a few small studies have followed young children for up to 9 years after sporadic cryptosporidiosis [ 13 , 15 ], we lack large studies that followed cryptosporidiosis outbreak cohorts for more than 36 months. The present study aimed to investigate whether post-infectious symptoms persisted for 5 years after a Cryptosporidium outbreak. Methods This retrospective cohort study was performed in 2016, 5 years after the outbreak of C. hominis IbA10G2 in Östersund, Sweden. Study population and data collection Two months after the outbreak in November 2010, we invited 1524 randomly selected inhabitants in Östersund, representing all ages, to complete a written questionnaire (outbreak questionnaire), which included questions on demographics, onset and symptoms of cryptosporidiosis, and underlying medical conditions. Among 1044 (69%) respondents, 481 (46.1%) were men and 563 (53.4%) were women. [ 6 ] The response rate was lowest among young adults (48.8%, age 20–29 years), and highest among older adults (> 87%, age > 60 years). Follow-ups were performed at 6 months and 2 years post-outbreak, and the results were reported in detail elsewhere [ 14 , 16 ]. In mid-March 2016, we sent a 5-year follow-up questionnaire, developed for this study (Additional files 1 and 2), by post to the respondents of the outbreak questionnaire. We included a pre-paid envelope to return the completed questionnaire. For children < 15 years old, we asked parents or guardians to complete the questionnaire. A reminder was sent after one month. The respondents reported experiences in the three months prior to completing the questionnaire concerning the following post-infectious symptoms: loss of appetite, weight loss, diarrhoea, watery diarrhoea, bloody diarrhoea, abdominal pain, nausea, vomiting, acid indigestion, bloating, a change in bowel habits, headache, eye pain, fatigue, stiff joints, joint pain, swollen joints, and joint discomfort. A blank area was included for reporting any other symptoms. We scanned the returned questionnaires optically and transformed them into an electronic database. Case and Non-case definitions A “case” was defined as a respondent that lived in Östersund in mid-January, 2011, and reported, in the outbreak questionnaire, new episodes of diarrhoea (≥ 3 episodes daily), and/or watery diarrhoea, with an onset between November 2, 2010 and January 30, 2011. A “non-case” was defined as any respondent that did not fulfil these criteria during the outbreak. Exclusion criteria We excluded respondents that, in the outbreak questionnaire, reported a prior diagnosis of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), or “other long-term bowel issues”. This exclusion obviated potential misclassifications. Data analyses The study population was stratified according to age and sex. Age was defined as the age at the time of the outbreak. The mean number of symptoms in each group was examined using the Student’s t-test. We examined associations between follow-up symptoms and case status with logistic regressions, adjusted for age and sex. The results are expressed as odds ratios (ORs) with 95% confidence intervals (95% CIs). Furthermore, associations between symptoms and case status were examined in different age groups (0–15 years, 16–40 years, 41–65 years, and > 65 years), with logistic regressions adjusted for sex. Missing values were excluded in the analyses. Analyses were performed with the statistical software, SPSS Statistic 24 (IBM, Armonk, NY, USA) Results Study population A total of 675 (69.0 %) individuals responded to the 5-year follow-up questionnaire. Compared to responders, non-responders were younger (30.8 vs. 46.0 years, p < 0.001), and more often men (51.5% vs. 43.7%, p = 0.014). There were no differences concerning case status. We excluded 2 individuals unable to answer due to dementia, and 47 individuals that reported IBD, IBS or other long-term bowel issues prior to the outbreak (Fig. 1 ). The final analysis included 626 individuals: 280 (44.7%) men and 346 (55.3%) women. Of these, we defined 262 (41.9%) as cases and 364 (58.1%) as non-cases. The median ages at the time of the outbreak were 43 (range 0–80) years in the case group, and 54 (range 0–92) years in the non-case group (Table 1 ). Table 1 Demographic characteristics of the study population, grouped by outbreak case status Characteristic Case n (%) Non-case n (%) Total n (%) Sex Female 145 (55.3) 201 (55.2) 346 (55.3) Male 117 (44.7) 163 (44.8) 280 (44.7) Age group, y (at outbreak) 0–15 44 (16.8) 50 (13.7) 94 (15.0) 16–40 72 (27.5) 68 (18.7) 140 (22.4) 41–65 109 (41.6) 152 (41.8) 261 (41.7) > 65 37 (14.1) 94 (25.8) 131 (20.9) Total Cases 262 364 626 Symptoms during follow-up Five years after the outbreak, 56.5% of the case group and 41.2% of the non-case group reported symptoms during the follow-up period. The case group reported a higher mean number of symptoms (3.8; median = 2, range = 0–17), than the non-case group (2.0; median = 0, range = 0–15; p < 0.001). The case group reported that symptoms during the prior three months lasted 10 days, compared to 7 days for the non-case group (median). The most frequent symptoms in the case group were headache, fatigue, and bloating. Compared to the non-case group, the case group was significantly more likely to report watery diarrhoea, diarrhoea, swollen joints, abdominal pain, bloating, joint discomfort, acid indigestion, changes in bowel habits, joint pain, ocular pain, nausea, and fatigue (Table 2 ). Symptoms associated with case status varied among age groups. Abdominal pain, acid indigestion, and alternating bowel habits were only observed in the > 65 year-old group; diarrhoea, swollen joints, and nausea were only observed in the 41–65 year-old group; and loss of appetite were only observed in the 16–40 year-old group. In the youngest age group (≤ 15 years), watery diarrhoea was the only symptom significantly associated with case status (OR: 11.1, 95% CI: 1.3–92.8). Table 2 Symptoms reported at follow-up by respondents and associations with case status Total 0–15 years 16–40 years 41–65 years > 65 years N = 626 N = 94 N = 140 N = 261 N = 131 Symptom Cases n (%) Non-cases n (%) OR (95% CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) Watery diarrhoea 43 (16.8) 14 (4.0) 4.5 (2.4–8.4) 11.1(1.3–92.8) 2.5 (0.9-7.0) 5.0 (2.0-12.5) . Diarrhoea 52 (20.2) 23 (6.4) 3.6 (2.2–6.2) 3.7 (0.7–19.4) 2.4 (1.0-6.1) 4.1 (1.9-9.0) 5.7 (1.0–34.0) Swollen joints 33 (12.9) 20 (5.8) 3.0 (1.6–5.4) . 7.5 (0.9–63.4) 2.7 (1.2–6.2) 2.7 (0.9–8.1) Abdominal pain 64 (25.1) 36 (10.1) 2.6 (1.7–4.1) 2.0 (0.8-5.0) 2.0 (0.9–4.5) 3.7 (0.7–8.1) 4.8 (1.1–21.2) Bloating 102 (39.4) 73 (20.9) 2.5 (1.7–3.6) 2.8 (0.8–8.2) 2.1 (1.0-4.3) 1.8 (1.1–3.4) 5.8 (2.3–14.6) Joint discomfort 82 (31.8) 62 (17.7) 2.4 (1.6–3.6) 2.7 (0.7–9.6) 3.5 (1.5–8.4) 2.1 (1.2–3.8) 1.7 (0.7–3.9) Stiff joints 71 (27.5) 58 (16.7) 2.3 (1.5–3.4) 2.2 (0.4–13.0) 5.8 (1.8–18.2) 2.1 (1.2–3.7) 1.2 (0.5–2.9) Acid indigestion 62 (23.9) 44 (12.8) 2.3 (1.5–3.5) 4.7 (0.9–24.2) 1.9 (0.8–4.6) 1.8 (0.9–3.3) 3.4 (1.3–8.9) Changes in bowel habits 47 (18.1) 32 (9.3) 2.2 (1.3–3.5) 2.9 (0.7–11.9) 2.5 (0.9-7.0) 1.5 (0.8-3.0) 4.3 (1.1–16.2) Joint pain 79 (30.4) 65 (18.7) 2.2 (1.5–3.3) 1.8 (0.5-7.0) 4.6 (1.7–12.5) 2.5 (1.4–4.4) 0.8 (0.3-2.0) Ocular pain 49 (19.3) 33 (9.5) 2.3 (1.4–3.7) 2.4 (0.7–7.9) 2.3 (0.9–6.1) 2.1 (0.9–4.6) 2.8 (1.0-7.6) Nausea 55 (22.0) 35 (9.9) 2.2 (1.4–3.6) 1.3 (0.5–3.3) 1.7 (0.7–3.9) 4.0 (1.8–9.1) 4.0 (0.8–19.1) Fatigue 106 (41.4) 85 (24.3) 2.0 (1.4–2.9) 1.8 (0.7–4.3) 2.1 (1.1–4.2) 2.2 (1.2–3.8) 1.6 (0.6–4.2) Headache 108 (42.2) 103 (29.3) 1.5 (1.0-2.1) 1.2 (0.5–2.8) 1.9 (0.9–3.8) 1.5 (0.8–2.6) 1.1 (0.4–3.4) Loss of appetite 23 (8.9) 14 (4.1) 2.0 (1.0–4.0) 1.5 (0.4–5.2) 12.1 (1.5–96.7) 0.9 (0.2–3.3) 2.6 (0.3–19.5) Vomiting 20 (7.9) 13 (3.7) 1.8 (0.9–3.7) 1.4 (0.4–4.5) 1.8 (0.5–6.5) 2.7 (0.6–11.5) . Weight loss 14 (5.5) 10 (2.9) 1.8 (0.8–4.1) 1.4 (0.3–6.8) 1.4 (0.2–8.9) 2.9 (0.5–16.4) 2.5 (0.5–13.3) Bolded values indicate a significant association Discussion In this retrospective cohort study, we demonstrated that post-infectious symptoms persisted for 5 years after a large waterborne outbreak caused by C. hominis in northern Sweden. Compared to the non-case group, the case group was more likely to report gastrointestinal symptoms, joint-related symptoms, ocular pain, and fatigue. Middle-aged individuals (41–65 years) seemed to be most affected, particularly by diarrhoea and different joint-related symptoms. The symptoms persisted to a lesser extent in children (≤ 15 years old) than in other age groups. To our knowledge, no other large studies have conducted such a long follow-up after an acute cryptosporidiosis. Our research group previously reported similar data from the same cohort, where follow-ups after 6-11months [ 16 ] and 2 years [ 14 ] demonstrated that the case group was more likely to have gastrointestinal and joint-related symptoms, compared to the non-case group. In another Swedish study, 271 individuals with sporadic infections from different types of cryptosporidiosis were followed in 2006–2008. After 25 to 36 months, 15% reported intermittent diarrhoea and 9% reported abdominal pains [ 17 ]. Acute gastroenteritis is known to increase the risk of IBS [ 18 , 19 ]. Follow-up studies on Giardia , another protozoan parasite that causes gastroenteritis, have shown similar post-infectious symptoms that persisted for up to 10 years [ 18 ]. Several putative factors have been implicated in the pathogenesis of IBS, including dysfunction of the innate immune system or the enteric nervous system and alterations in the faecal microbiota [ 20 ]. However, additional studies are needed to clarify the interplay between these factors to reach a plausible hypothesis for the pathophysiologic mechanism of long-term symptoms after a Cryptosporidium infection. Overall, the symptoms most frequently reported in our case group were headache, fatigue, and bloating. In the most affected age group (41–65 year-olds), diarrhoea, joint-related symptoms, nausea, and fatigue were most highly associated with cryptosporidiosis. These data were consistent with results reported in a systematic review based on pooled estimates from 8 studies on the health sequelae of cryptosporidiosis, with follow-up periods of 2—36 months. In that study, the most common long-term sequelae were diarrhoea (25%), abdominal pain (25%), nausea (24%), fatigue (25%), and headache (21%) [ 11 ]. The group of children (0–15 years old) in our study was small (n = 94), and this group reported watery diarrhoea, but no other persisting symptoms. However, previous studies have reported that particularly young children (< 2 years old) were vulnerable to acute infections and the consequences [ 7 ], and IBS or IBS-like symptoms after cryptosporidiosis occurred at a higher rate in children than in adults [ 9 ]. In contrast, in our cohort, at the two-year follow-up, the children did not report any significant persistent symptoms, other than headaches [ 14 ]. However, it is difficult to identify and define sequelae in young children, and adults have been over-represented in most large studies [ 11 ]. Thus, more research is needed with a particular focus on long-term persistent symptoms in children. Conclusion In summary, our findings indicated that post-infectious symptoms, due to cryptosporidiosis, could persist for up to 5 years, a longer time than any previous study has documented. This finding suggested that the long-term health consequences of cryptosporidiosis may be underestimated, both on an individual level and on the global level. Limitations One limitation of this study was that our case definition was based on self-reported symptoms, and we lacked laboratory confirmation. This limitation might have led to misclassification of case-status in some individuals. However, during the outbreak in 2010, cryptosporidium was detected in the drinking water; in addition, 149 stool samples were collected among individuals with diarrhoea, and all were positive for C. hominis and negative for other gastrointestinal pathogens [ 6 ]. Another limitation was that we did not determine whether participants had a chronic Cryptosporidium infection, which could potentially have caused the follow-up symptoms. However, during the 2-year follow-up, study participants were invited to submit stool samples (n = 183), and these were all negative for Cryptosporidium , based on a standard concentration determination technique with modified Ziehl–Neelsen staining [ 14 ]. Moreover, it is possible that individuals with chronic intermittent diarrhoea might have been misclassified as cases during the outbreak. These individuals might be more likely to have had similar symptoms at follow-ups, which could have led to an overestimation of the associations. However, we attempted to minimize this effect by excluding individuals that reported a pre-existing IBD or IBS diagnosis, or any other long-term gastrointestinal problems, prior to the outbreak. On the other hand, some participants might have had subclinical Cryptosporidium infections during the outbreak [ 2 ]. If these participants had experienced and reported post-infectious symptoms, they would have contributed to the prevalence of symptoms in the non-case group. That situation could have led to an underestimation of the associations. Although the long-term gastrointestinal symptoms reported by many participants were likely to be due to IBS, we could not fully diagnose IBS. A validated questionnaire on the Rome IV criteria is typically used to diagnose IBS [ 21 ]. However, the questionnaire is lengthy, and we were concerned that including the full questionnaire might reduce the overall response rate. Therefore, we decided not to include it in full, but to base our questions concerning gastrointestinal symptoms on those criteria. Lastly, there was a risk that individuals that were infected during the outbreak (i.e., cases) might be more prone to note, remember, and report on their symptoms, compared to individuals that were not infected. Abbreviations C. hominis Cryptosporidium hominis CI Confidence interval IBD Inflammatory bowel disease IBS Irritable bowel syndrome OR Odds ratio Declarations Ethics approval and consent to participate The Regional Ethical Review Board in Umeå approved this study (2015/495-31Ö). The respondents were given information about the study in a written letter, and participants provided consent by completing the written questionnaire. Consent for publication Not applicable. Availability of data and material The datasets used in the current study are available from the corresponding author on reasonable request. Competing interests The authors declare no competing interests. Funding This study was funded by grants from the County Council Jämtland Härjedalen. Authors’ contributions ML and MW were the main contributors to the design of the questionnaires. All authors contributed to the analysis and interpretation of the data. MS and MA were the major contributors to writing the manuscript. All authors read and approved the final manuscript. Acknowledgements The authors wish to acknowledge the unit of Epidemiology, Swedish Institute for Infectious Disease Control, for contributions to the design of the questionnaires. References 1. Checkley W, White AC Jr, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2015;15:85-94. 2. Bouzid M, Hunter PR, Chalmers RM, Tyler KM. Cryptosporidium pathogenicity and virulence. Clin Microbiol Rev 2013;26:115-34. 3. Chalmers RM, Davies AP. Minireview: clinical cryptosporidiosis. Exp Parasitol. 2010;124:138-46. 4. Efstratiou A, Ongerth JE, Karanis P. Waterborne transmission of protozoan parasites: Review of worlwide outbreaks - an update 2011-2016. Water Research. 2017;114:14-22. 5. Mac Kenzie WR, Hoxie NJ, Proctor ME, Gradus MS, Blair KA, Peterson DE, et al. A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply. N Engl J Med. 1994;331:161-67. 6. Widerstrom M, Schonning C, Lilja M, Lebbad M, Ljung T, Allestam G, et al. Large outbreak of Cryptosporidium hominis infection transmitted through the public water supply, Sweden. Emerg Infect Dis . 2014;20:581-89. 7. Caccio SM, Chalmers RM: Human cryptosporidiosis in Europe. Clin Microbiol Infect. 2016;22:471-80. 8. Hunter PR, Hughes S, Woodhouse S, Raj N, Syed Q, Chalmers RM, et al. Health sequelae of human cryptosporidiosis in immunocompetent patients. Clin Infect Dis. 2004;39:504-10. 9. Carter BL, Stiff RE, Elwin K, Hutchings HA, Mason BW, Davies AP, et al. Health sequelae of human cryptosporidiosis-a 12-month prospective follow-up study. Eur J Clin Microbiol Infect Dis. 2019; 38:1709-17. 10. Igloi Z, Mughini-Gras L, Nic Lochlainn L, Barrasa A, Sane J, Mooij S, et al. Long-term sequelae of sporadic cryptosporidiosis: a follow-up study. Eur J Clin Microbiol Infect Dis. 2018;37:1377-84. 11. Carter B, Chalmers R, Davies A. Health sequelae of human cryptosporidiosis in industrialised countries: a systematic review. Parasites & Vectors. 2020;13:443. 12. Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al.The Burden of Cryptosporidium diarrheal disease among children < 24 months of age in moderate/high mortality regions of subSaharan Africa and south Asia, utilizing data from the global enteric multicenter study (GEMS). PLoS Negl Trop Dis. 2016;10: e0004729. 13. Guerrant DI, Moore SR, Lima AAM, Patrick PD, Schorling JB, Guerrant RL. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven years later in a poor urban community in northeast Brazil. Am J Trop Med Hyg . 1999;61:707-13. 14. Lilja M, Widerstrom M, Lindh J. Persisting post-infection symptoms 2 years after a large waterborne outbreak of Cryptosporidium hominis in northern Sweden. BMC Res Notes. 2018;11:625. 15. Berkman DS, Lescano AG, Gilman RH, Lopez SL, Black MM. Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. Lancet. 2002;359:564-71. 16. Rehn M, Wallensten A, Widerstrom M, Lilja M, Grunewald M, Stenmark S, et al. Post-infection symptoms following two large waterborne outbreaks of Cryptosporidium hominis in Northern Sweden, 2010-2011. BMC Public Health. 2015;15:529. 17. Insulander M, Silverlås C, Lebbad M, Karlsson L. Mattsson JG, Svenungsson B. Molecular epidemiology and clinical manifestations of human cryptosporidiosis in Sweden. Epidemiol Infect. 2013;141:1009-20. 18. Litleskare S, Rortveit G, Eide GE, Hanevik K, Langeland N, Wensaas KA. Prevalence of irritable bowel syndrome and chronic fatigue 10 years after Giardia infection. Clin Gastroenterol Hepatol. 2018;16:1064-72. 19. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:535-44. 20. Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1:133-46. 21. Palsson OS, Whitehead WE, van Tilburg MA, Chang L, Chey W, Crowell MD, et al. Rome IV Diagnostic questionnaires and tables for investigators and clinicians. Gastroenterology. 2016;150:1481-91. Supplementary Files AdditionalFile1Swe.pdf AdditionalFile2Eng.pdf Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Major revision 13 Sep, 2021 Review # 2 received at journal 12 Sep, 2021 Reviewer # 2 agreed at journal 29 Aug, 2021 Review # 1 received at journal 13 Aug, 2021 Reviewer # 1 agreed at journal 31 Jul, 2021 Reviewers invited by journal 16 Jul, 2021 Editor assigned by journal 11 Jul, 2021 Submission checks completed at journal 11 Jul, 2021 Editor invited by journal 11 Jul, 2021 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-742939","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research note","associatedPublications":[],"authors":[{"id":41218524,"identity":"aa5c6a21-3c7c-4a5c-80b9-70838fa8b73d","order_by":0,"name":"Malin Sjöström","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA30lEQVRIie3RMQrCMBSA4ZQHulQ6F/EIQqDQSXqWloCTg6NTqYsuHqA9hGvmlIAuxa4Bp+IFUro4OGhKK06xo2D+IRDIx0sIQibTTwYJU2u3WwwhVk9atRxG+nFq4d/BfJ9v+RrFY8cpT7JeldExDUFKDfGLKOEp4uCmBLKMXiMqwpGb6gh7ERsxwAIAJh0BW0fKSpEYcMkVuSgCzUNHRDsFADOiCFMETXXP94Wagtu3eFZGiUeLaucetBcjvLE3MXGc/IZqGszomXB5141pw4h87N4/pS8YdMpkMpn+sycyOFCqhu/hmAAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0000-0003-0868-6249","institution":"Department of Public Health and Clinical Medicine, Umeå University","correspondingAuthor":true,"prefix":"","firstName":"Malin","middleName":"","lastName":"Sjöström","suffix":""},{"id":41218525,"identity":"ecbcbef8-419b-4956-b6fd-14e19871e201","order_by":1,"name":"Malin Arvidsson","email":"","orcid":"","institution":"Department of Clinical Microbiology, Umeå University","correspondingAuthor":false,"prefix":"","firstName":"Malin","middleName":"","lastName":"Arvidsson","suffix":""},{"id":41218526,"identity":"b582c7b8-c2fa-4b2b-ac5b-78b4d100cfa6","order_by":2,"name":"Lars Söderström","email":"","orcid":"","institution":"Unit of Research, Education and Development, Östersund Hospital","correspondingAuthor":false,"prefix":"","firstName":"Lars","middleName":"","lastName":"Söderström","suffix":""},{"id":41218527,"identity":"2af54496-bd61-4f99-8300-57119e42302a","order_by":3,"name":"Mikael Lilja","email":"","orcid":"","institution":"Department of PUblic Health and Clinical Medicin, Unit of Research, Education, and Development, Östersund Hospital, Umeå University","correspondingAuthor":false,"prefix":"","firstName":"Mikael","middleName":"","lastName":"Lilja","suffix":""},{"id":41218528,"identity":"a9ec07c5-a315-4ca0-866a-3bdae90dd0fb","order_by":4,"name":"Johan Lindh","email":"","orcid":"","institution":"Department of Cell and Molecular Biology, BMC, Uppsala University","correspondingAuthor":false,"prefix":"","firstName":"Johan","middleName":"","lastName":"Lindh","suffix":""},{"id":41218529,"identity":"3c7d698b-faa7-491f-9dcc-b94adf88cd08","order_by":5,"name":"Micael Widerström","email":"","orcid":"","institution":"Department of Clinical Microbiology, Umeå University","correspondingAuthor":false,"prefix":"","firstName":"Micael","middleName":"","lastName":"Widerström","suffix":""}],"badges":[],"createdAt":"2021-07-22 13:30:24","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-742939/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-742939/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":11824327,"identity":"186321c0-1922-4169-997e-4c02e31e52e1","added_by":"auto","created_at":"2021-07-26 20:54:38","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":49491,"visible":true,"origin":"","legend":"Flow chart of the case selection process\nCase = New episodes of diarrhoea (≥ 3 episodes daily), and/or watery diarrhoea between November 1, 2012 and January 31, 2011, in respondent residing in Östersund in mid-January 2011\n\nNon-case = Any respondent not fulfilling the case criteria during the outbreak. \n\nIBD = Inflammatory bowel disease \nIBS = Irritable bowel syndrome\n \n","description":"","filename":"Fig1.png","url":"https://assets-eu.researchsquare.com/files/rs-742939/v1/caf1ad3236768001227b0aac.png"},{"id":15674122,"identity":"8ef2da50-ff2c-4e63-b934-34fc38ff8640","added_by":"auto","created_at":"2021-11-18 14:21:28","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":416923,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-742939/v1/aa3f6c71-9477-4393-849c-664d8a8e5e4d.pdf"},{"id":11824329,"identity":"e797ffb0-4b5c-4329-865e-b0dfd06f5998","added_by":"auto","created_at":"2021-07-26 20:54:38","extension":"pdf","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":111808,"visible":true,"origin":"","legend":"","description":"","filename":"AdditionalFile1Swe.pdf","url":"https://assets-eu.researchsquare.com/files/rs-742939/v1/108349274a59cd316a07e614.pdf"},{"id":11824328,"identity":"c7e834de-2fff-4e78-9870-381b30c6ba07","added_by":"auto","created_at":"2021-07-26 20:54:38","extension":"pdf","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":114395,"visible":true,"origin":"","legend":"","description":"","filename":"AdditionalFile2Eng.pdf","url":"https://assets-eu.researchsquare.com/files/rs-742939/v1/6eaf842879c70f2e53488430.pdf"}],"financialInterests":"","formattedTitle":"\u003cp\u003eOutbreak of \u003cem\u003eCryptosporidium hominis\u003c/em\u003e in northern Sweden: persisting symptoms in a five-year follow-up\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003e \u003cem\u003eCryptosporidium\u003c/em\u003e is a protozoan parasite that can infect humans and animals. More than 20 species have been identified, but \u003cem\u003eC. hominis\u003c/em\u003e and \u003cem\u003eC. parvum c\u003c/em\u003eause the majority of infections in humans [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. \u003cem\u003eCryptosporidium\u003c/em\u003e is mainly transmitted through the faecal-oral route, either through oocyst-contaminated water or food or through direct contact with an infected person or animal [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eCryptosporidiosis occurs worldwide and in all age groups [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Many small waterborne outbreaks have been reported globally, but only a few large outbreaks have been reported [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. To date, the largest outbreak occurred in Milwaukee, Wisconsin, in 1993. In that outbreak, 400,000 people were infected through the public water supply [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. In November 2010, \u0026Ouml;stersund, a city in northern Sweden, experienced a large outbreak of acute diarrhoea, caused by \u003cem\u003eC. hominis\u003c/em\u003e IbA10G2, which was transmitted through the public water supply. Approximately 27,000 (45%) of 59,000 inhabitants reported symptoms compatible with cryptosporidiosis [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe most common symptoms of cryptosporidiosis are watery diarrhoea, nausea, vomiting, fever, and abdominal pain. The symptoms typically last a few days to 2\u0026ndash;3 weeks [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e], but the infection can also be asymptomatic. [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e] Children, particularly those\u0026thinsp;\u0026lt;\u0026thinsp;2 years old, often display more severe symptoms than adults [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e \u003cp\u003ePost-infectious symptoms after cryptosporidiosis have been described in several studies [\u003cspan additionalcitationids=\"CR9\" citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. Long-term sequelae are common after \u003cem\u003eC. hominis\u003c/em\u003e infections, including diarrhoea, abdominal pain, nausea, fatigue, and headache [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Among children in developing countries, cryptosporidiosis has been associated with increased mortality (12), impaired physical fitness, and impaired cognitive function [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Two years after the outbreak in \u0026Ouml;stersund, individuals that had been infected during the outbreak (cases) were more likely than those that had not been infected (non-cases) to report gastrointestinal symptoms, fatigue, headache, or joint-related symptoms [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. Although a few small studies have followed young children for up to 9 years after sporadic cryptosporidiosis [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e], we lack large studies that followed cryptosporidiosis outbreak cohorts for more than 36 months.\u003c/p\u003e \u003cp\u003eThe present study aimed to investigate whether post-infectious symptoms persisted for 5 years after a \u003cem\u003eCryptosporidium\u003c/em\u003e outbreak.\u003c/p\u003e "},{"header":"Methods","content":" \u003cp\u003eThis retrospective cohort study was performed in 2016, 5 years after the outbreak of \u003cem\u003eC. hominis\u003c/em\u003e IbA10G2 in \u0026Ouml;stersund, Sweden.\u003c/p\u003e \u003cdiv id=\"Sec2\" class=\"Section2\"\u003e \u003ch2\u003eStudy population and data collection\u003c/h2\u003e \u003cp\u003eTwo months after the outbreak in November 2010, we invited 1524 randomly selected inhabitants in \u0026Ouml;stersund, representing all ages, to complete a written questionnaire (outbreak questionnaire), which included questions on demographics, onset and symptoms of cryptosporidiosis, and underlying medical conditions. Among 1044 (69%) respondents, 481 (46.1%) were men and 563 (53.4%) were women. [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e] The response rate was lowest among young adults (48.8%, age 20\u0026ndash;29 years), and highest among older adults (\u0026gt;\u0026thinsp;87%, age\u0026thinsp;\u0026gt;\u0026thinsp;60 years). Follow-ups were performed at 6 months and 2 years post-outbreak, and the results were reported in detail elsewhere [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn mid-March 2016, we sent a 5-year follow-up questionnaire, developed for this study (Additional files 1 and 2), by post to the respondents of the outbreak questionnaire. We included a pre-paid envelope to return the completed questionnaire. For children\u0026thinsp;\u0026lt;\u0026thinsp;15 years old, we asked parents or guardians to complete the questionnaire. A reminder was sent after one month. The respondents reported experiences in the three months prior to completing the questionnaire concerning the following post-infectious symptoms: loss of appetite, weight loss, diarrhoea, watery diarrhoea, bloody diarrhoea, abdominal pain, nausea, vomiting, acid indigestion, bloating, a change in bowel habits, headache, eye pain, fatigue, stiff joints, joint pain, swollen joints, and joint discomfort. A blank area was included for reporting any other symptoms. We scanned the returned questionnaires optically and transformed them into an electronic database.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eCase and Non-case definitions\u003c/h2\u003e \u003cp\u003eA \u0026ldquo;case\u0026rdquo; was defined as a respondent that lived in \u0026Ouml;stersund in mid-January, 2011, and reported, in the outbreak questionnaire, new episodes of diarrhoea (\u0026ge;\u0026thinsp;3 episodes daily), and/or watery diarrhoea, with an onset between November 2, 2010 and January 30, 2011.\u003c/p\u003e \u003cp\u003eA \u0026ldquo;non-case\u0026rdquo; was defined as any respondent that did not fulfil these criteria during the outbreak.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eExclusion criteria\u003c/h2\u003e \u003cp\u003eWe excluded respondents that, in the outbreak questionnaire, reported a prior diagnosis of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), or \u0026ldquo;other long-term bowel issues\u0026rdquo;. This exclusion obviated potential misclassifications.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eData analyses\u003c/h2\u003e \u003cp\u003eThe study population was stratified according to age and sex. Age was defined as the age at the time of the outbreak. The mean number of symptoms in each group was examined using the Student\u0026rsquo;s t-test. We examined associations between follow-up symptoms and case status with logistic regressions, adjusted for age and sex. The results are expressed as odds ratios (ORs) with 95% confidence intervals (95% CIs). Furthermore, associations between symptoms and case status were examined in different age groups (0\u0026ndash;15 years, 16\u0026ndash;40 years, 41\u0026ndash;65 years, and \u0026gt;\u0026thinsp;65 years), with logistic regressions adjusted for sex. Missing values were excluded in the analyses. Analyses were performed with the statistical software, SPSS Statistic 24 (IBM, Armonk, NY, USA)\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eStudy population\u003c/h2\u003e \u003cp\u003eA total of 675 (69.0 %) individuals responded to the 5-year follow-up questionnaire. Compared to responders, non-responders were younger (30.8 vs. 46.0 years, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), and more often men (51.5% vs. 43.7%, p\u0026thinsp;=\u0026thinsp;0.014). There were no differences concerning case status.\u003c/p\u003e \u003cp\u003eWe excluded 2 individuals unable to answer due to dementia, and 47 individuals that reported IBD, IBS or other long-term bowel issues prior to the outbreak (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThe final analysis included 626 individuals: 280 (44.7%) men and 346 (55.3%) women. Of these, we defined 262 (41.9%) as cases and 364 (58.1%) as non-cases. The median ages at the time of the outbreak were 43 (range 0\u0026ndash;80) years in the case group, and 54 (range 0\u0026ndash;92) years in the non-case group (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eDemographic characteristics of the study population, grouped by outbreak case status\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCharacteristic\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCase n (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNon-case n (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eTotal n (%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eSex\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e145 (55.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e201 (55.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e346 (55.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e117 (44.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e163 (44.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e280 (44.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cem\u003eAge group, y (at outbreak)\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e0\u0026ndash;15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e44 (16.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e50 (13.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e94 (15.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e16\u0026ndash;40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e72 (27.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e68 (18.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e140 (22.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e41\u0026ndash;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e109 (41.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e152 (41.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e261 (41.7)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e37 (14.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e94 (25.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e131 (20.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTotal Cases\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e262\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e364\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e626\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eSymptoms during follow-up\u003c/h2\u003e \u003cp\u003eFive years after the outbreak, 56.5% of the case group and 41.2% of the non-case group reported symptoms during the follow-up period. The case group reported a higher mean number of symptoms (3.8; median\u0026thinsp;=\u0026thinsp;2, range\u0026thinsp;=\u0026thinsp;0\u0026ndash;17), than the non-case group (2.0; median\u0026thinsp;=\u0026thinsp;0, range\u0026thinsp;=\u0026thinsp;0\u0026ndash;15; p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). The case group reported that symptoms during the prior three months lasted 10 days, compared to 7 days for the non-case group (median). The most frequent symptoms in the case group were headache, fatigue, and bloating.\u003c/p\u003e \u003cp\u003eCompared to the non-case group, the case group was significantly more likely to report watery diarrhoea, diarrhoea, swollen joints, abdominal pain, bloating, joint discomfort, acid indigestion, changes in bowel habits, joint pain, ocular pain, nausea, and fatigue (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). Symptoms associated with case status varied among age groups. Abdominal pain, acid indigestion, and alternating bowel habits were only observed in the \u0026gt;\u0026thinsp;65 year-old group; diarrhoea, swollen joints, and nausea were only observed in the 41\u0026ndash;65 year-old group; and loss of appetite were only observed in the 16\u0026ndash;40 year-old group. In the youngest age group (\u0026le;\u0026thinsp;15 years), watery diarrhoea was the only symptom significantly associated with case status (OR: 11.1, 95% CI: 1.3\u0026ndash;92.8).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSymptoms reported at follow-up by respondents and associations with case status\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"8\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c4\" namest=\"c2\"\u003e \u003cp\u003eTotal\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u0026ndash;15 years\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003e16\u0026ndash;40 years\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003e41\u0026ndash;65 years\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;65 years\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colspan=\"3\" nameend=\"c4\" namest=\"c2\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;626\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;94\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;140\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;261\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eN\u0026thinsp;=\u0026thinsp;131\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eSymptom\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCases n (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNon-cases n (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eOR (95% CI)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eOR (95%CI)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOR (95%CI)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eOR (95%CI)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eOR (95%CI)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWatery diarrhoea\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e43 (16.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14 (4.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e4.5 (2.4\u0026ndash;8.4)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e11.1(1.3\u0026ndash;92.8)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2.5 (0.9-7.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e5.0 (2.0-12.5)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e.\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDiarrhoea\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e52 (20.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23 (6.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e3.6 (2.2\u0026ndash;6.2)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3.7 (0.7\u0026ndash;19.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2.4 (1.0-6.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e4.1 (1.9-9.0)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e5.7 (1.0\u0026ndash;34.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSwollen joints\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e33 (12.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e20 (5.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e3.0 (1.6\u0026ndash;5.4)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7.5 (0.9\u0026ndash;63.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e2.7 (1.2\u0026ndash;6.2)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e2.7 (0.9\u0026ndash;8.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAbdominal pain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e64 (25.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36 (10.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e2.6 (1.7\u0026ndash;4.1)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.0 (0.8-5.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2.0 (0.9\u0026ndash;4.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3.7 (0.7\u0026ndash;8.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cb\u003e4.8 (1.1\u0026ndash;21.2)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBloating\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e102 (39.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e73 (20.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e2.5 (1.7\u0026ndash;3.6)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.8 (0.8\u0026ndash;8.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2.1 (1.0-4.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e1.8 (1.1\u0026ndash;3.4)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cb\u003e5.8 (2.3\u0026ndash;14.6)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eJoint discomfort\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e82 (31.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e62 (17.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e2.4 (1.6\u0026ndash;3.6)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.7 (0.7\u0026ndash;9.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e3.5 (1.5\u0026ndash;8.4)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e2.1 (1.2\u0026ndash;3.8)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.7 (0.7\u0026ndash;3.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStiff joints\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e71 (27.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e58 (16.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e2.3 (1.5\u0026ndash;3.4)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.2 (0.4\u0026ndash;13.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e5.8 (1.8\u0026ndash;18.2)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e2.1 (1.2\u0026ndash;3.7)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.2 (0.5\u0026ndash;2.9)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAcid indigestion\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e62 (23.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e44 (12.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e2.3 (1.5\u0026ndash;3.5)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4.7 (0.9\u0026ndash;24.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.9 (0.8\u0026ndash;4.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.8 (0.9\u0026ndash;3.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cb\u003e3.4 (1.3\u0026ndash;8.9)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eChanges in bowel habits\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e47 (18.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e32 (9.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e2.2 (1.3\u0026ndash;3.5)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.9 (0.7\u0026ndash;11.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2.5 (0.9-7.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.5 (0.8-3.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cb\u003e4.3 (1.1\u0026ndash;16.2)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eJoint pain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e79 (30.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e65 (18.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e2.2 (1.5\u0026ndash;3.3)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.8 (0.5-7.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e4.6 (1.7\u0026ndash;12.5)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e2.5 (1.4\u0026ndash;4.4)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.8 (0.3-2.0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOcular pain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e49 (19.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33 (9.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e2.3 (1.4\u0026ndash;3.7)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.4 (0.7\u0026ndash;7.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e2.3 (0.9\u0026ndash;6.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2.1 (0.9\u0026ndash;4.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e2.8 (1.0-7.6)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNausea\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e55 (22.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e35 (9.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e2.2 (1.4\u0026ndash;3.6)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.3 (0.5\u0026ndash;3.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.7 (0.7\u0026ndash;3.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e4.0 (1.8\u0026ndash;9.1)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e4.0 (0.8\u0026ndash;19.1)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFatigue\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e106 (41.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e85 (24.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e2.0 (1.4\u0026ndash;2.9)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.8 (0.7\u0026ndash;4.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e2.1 (1.1\u0026ndash;4.2)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e2.2 (1.2\u0026ndash;3.8)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.6 (0.6\u0026ndash;4.2)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHeadache\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e108 (42.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e103 (29.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.5 (1.0-2.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.2 (0.5\u0026ndash;2.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.9 (0.9\u0026ndash;3.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.5 (0.8\u0026ndash;2.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.1 (0.4\u0026ndash;3.4)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLoss of appetite\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e23 (8.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14 (4.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.0 (1.0\u0026ndash;4.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.5 (0.4\u0026ndash;5.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e12.1 (1.5\u0026ndash;96.7)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.9 (0.2\u0026ndash;3.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e2.6 (0.3\u0026ndash;19.5)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVomiting\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e20 (7.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13 (3.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.8 (0.9\u0026ndash;3.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.4 (0.4\u0026ndash;4.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.8 (0.5\u0026ndash;6.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2.7 (0.6\u0026ndash;11.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e.\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWeight loss\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e14 (5.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10 (2.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.8 (0.8\u0026ndash;4.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.4 (0.3\u0026ndash;6.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1.4 (0.2\u0026ndash;8.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2.9 (0.5\u0026ndash;16.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e2.5 (0.5\u0026ndash;13.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"8\"\u003eBolded values indicate a significant association\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this retrospective cohort study, we demonstrated that post-infectious symptoms persisted for 5 years after a large waterborne outbreak caused by \u003cem\u003eC. hominis\u003c/em\u003e in northern Sweden. Compared to the non-case group, the case group was more likely to report gastrointestinal symptoms, joint-related symptoms, ocular pain, and fatigue. Middle-aged individuals (41\u0026ndash;65 years) seemed to be most affected, particularly by diarrhoea and different joint-related symptoms. The symptoms persisted to a lesser extent in children (\u0026le;\u0026thinsp;15 years old) than in other age groups.\u003c/p\u003e \u003cp\u003eTo our knowledge, no other large studies have conducted such a long follow-up after an acute cryptosporidiosis. Our research group previously reported similar data from the same cohort, where follow-ups after 6-11months [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e] and 2 years [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e] demonstrated that the case group was more likely to have gastrointestinal and joint-related symptoms, compared to the non-case group. In another Swedish study, 271 individuals with sporadic infections from different types of cryptosporidiosis were followed in 2006\u0026ndash;2008. After 25 to 36 months, 15% reported intermittent diarrhoea and 9% reported abdominal pains [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eAcute gastroenteritis is known to increase the risk of IBS [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Follow-up studies on \u003cem\u003eGiardia\u003c/em\u003e, another protozoan parasite that causes gastroenteritis, have shown similar post-infectious symptoms that persisted for up to 10 years [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. Several putative factors have been implicated in the pathogenesis of IBS, including dysfunction of the innate immune system or the enteric nervous system and alterations in the faecal microbiota [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. However, additional studies are needed to clarify the interplay between these factors to reach a plausible hypothesis for the pathophysiologic mechanism of long-term symptoms after a \u003cem\u003eCryptosporidium\u003c/em\u003e infection.\u003c/p\u003e \u003cp\u003eOverall, the symptoms most frequently reported in our case group were headache, fatigue, and bloating. In the most affected age group (41\u0026ndash;65 year-olds), diarrhoea, joint-related symptoms, nausea, and fatigue were most highly associated with cryptosporidiosis. These data were consistent with results reported in a systematic review based on pooled estimates from 8 studies on the health sequelae of cryptosporidiosis, with follow-up periods of 2\u0026mdash;36 months. In that study, the most common long-term sequelae were diarrhoea (25%), abdominal pain (25%), nausea (24%), fatigue (25%), and headache (21%) [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe group of children (0\u0026ndash;15 years old) in our study was small (n\u0026thinsp;=\u0026thinsp;94), and this group reported watery diarrhoea, but no other persisting symptoms. However, previous studies have reported that particularly young children (\u0026lt;\u0026thinsp;2 years old) were vulnerable to acute infections and the consequences [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e], and IBS or IBS-like symptoms after cryptosporidiosis occurred at a higher rate in children than in adults [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. In contrast, in our cohort, at the two-year follow-up, the children did not report any significant persistent symptoms, other than headaches [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. However, it is difficult to identify and define sequelae in young children, and adults have been over-represented in most large studies [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Thus, more research is needed with a particular focus on long-term persistent symptoms in children.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIn summary, our findings indicated that post-infectious symptoms, due to cryptosporidiosis, could persist for up to 5 years, a longer time than any previous study has documented. This finding suggested that the long-term health consequences of cryptosporidiosis may be underestimated, both on an individual level and on the global level.\u003c/p\u003e "},{"header":"Limitations","content":"\u003cp\u003eOne limitation of this study was that our case definition was based on self-reported symptoms, and we lacked laboratory confirmation. This limitation might have led to misclassification of case-status in some individuals. However, during the outbreak in 2010, cryptosporidium was detected in the drinking water; in addition, 149 stool samples were collected among individuals with diarrhoea, and all were positive \u003cem\u003efor C. hominis\u003c/em\u003e and negative for other gastrointestinal pathogens [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eAnother limitation was that we did not determine whether participants had a chronic \u003cem\u003eCryptosporidium\u003c/em\u003e infection, which could potentially have caused the follow-up symptoms. However, during the 2-year follow-up, study participants were invited to submit stool samples (n\u0026thinsp;=\u0026thinsp;183), and these were all negative for \u003cem\u003eCryptosporidium\u003c/em\u003e, based on a standard concentration determination technique with modified Ziehl\u0026ndash;Neelsen staining [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eMoreover, it is possible that individuals with chronic intermittent diarrhoea might have been misclassified as cases during the outbreak. These individuals might be more likely to have had similar symptoms at follow-ups, which could have led to an overestimation of the associations. However, we attempted to minimize this effect by excluding individuals that reported a pre-existing IBD or IBS diagnosis, or any other long-term gastrointestinal problems, prior to the outbreak. On the other hand, some participants might have had subclinical \u003cem\u003eCryptosporidium\u003c/em\u003e infections during the outbreak [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. If these participants had experienced and reported post-infectious symptoms, they would have contributed to the prevalence of symptoms in the non-case group. That situation could have led to an underestimation of the associations.\u003c/p\u003e \u003cp\u003eAlthough the long-term gastrointestinal symptoms reported by many participants were likely to be due to IBS, we could not fully diagnose IBS. A validated questionnaire on the Rome IV criteria is typically used to diagnose IBS [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. However, the questionnaire is lengthy, and we were concerned that including the full questionnaire might reduce the overall response rate. Therefore, we decided not to include it in full, but to base our questions concerning gastrointestinal symptoms on those criteria.\u003c/p\u003e \u003cp\u003eLastly, there was a risk that individuals that were infected during the outbreak (i.e., cases) might be more prone to note, remember, and report on their symptoms, compared to individuals that were not infected.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eC. hominis\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eCryptosporidium hominis\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eCI\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eConfidence interval\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eIBD\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eInflammatory bowel disease\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eIBS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eIrritable bowel syndrome\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eOR\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eOdds ratio\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003ch2\u003eEthics approval and consent to participate\u0026nbsp;\u003c/h2\u003e\n\u003cp\u003eThe Regional Ethical Review Board in Ume\u0026aring; approved this study (2015/495-31\u0026Ouml;). The respondents were given information about the study in a written letter, and participants provided consent by completing the written questionnaire.\u003c/p\u003e\n\u003ch2\u003eConsent for publication\u0026nbsp;\u003c/h2\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003ch2\u003eAvailability of data and material\u003c/h2\u003e\n\u003cp\u003eThe datasets used in the current study are available from the corresponding\u003c/p\u003e\n\u003cp\u003eauthor on reasonable request.\u003c/p\u003e\n\u003ch2\u003eCompeting interests\u0026nbsp;\u003c/h2\u003e\n\u003cp\u003eThe authors declare no competing interests.\u003c/p\u003e\n\u003ch2\u003eFunding\u0026nbsp;\u003c/h2\u003e\n\u003cp\u003eThis study was funded by grants from the County Council J\u0026auml;mtland H\u0026auml;rjedalen.\u0026nbsp;\u003c/p\u003e\n\u003ch2\u003eAuthors\u0026rsquo; contributions\u0026nbsp;\u003c/h2\u003e\n\u003cp\u003eML and MW were the main contributors to the design of the questionnaires. All authors contributed to the analysis and interpretation of the data. MS and MA were the major contributors to writing the manuscript. All authors read and approved the final manuscript.\u0026nbsp;\u003c/p\u003e\n\u003ch2\u003eAcknowledgements\u003c/h2\u003e\n\u003cp\u003eThe authors wish to acknowledge the unit of Epidemiology, Swedish Institute for Infectious Disease Control, for contributions to the design of the questionnaires.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003cp\u003e1. \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Checkley W, White AC Jr, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2015;15:85-94.\u003c/p\u003e\n\u003cp\u003e2. \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Bouzid M, Hunter PR, Chalmers RM, Tyler KM. Cryptosporidium pathogenicity and virulence. Clin Microbiol Rev\u003cem\u003e\u0026nbsp;\u003c/em\u003e2013;26:115-34.\u003c/p\u003e\n\u003cp\u003e3. \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Chalmers RM, Davies AP. Minireview: clinical cryptosporidiosis. Exp Parasitol.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2010;124:138-46.\u003c/p\u003e\n\u003cp\u003e4. \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Efstratiou A, Ongerth JE, Karanis P. Waterborne transmission of protozoan parasites: Review of worlwide outbreaks - an update 2011-2016. Water Research.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2017;114:14-22.\u003c/p\u003e\n\u003cp\u003e5. \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Mac Kenzie WR, Hoxie NJ, Proctor ME, Gradus MS, Blair KA, Peterson DE,\u003cem\u003e\u0026nbsp;\u003c/em\u003eet al. A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply. N Engl J Med. 1994;331:161-67.\u003c/p\u003e\n\u003cp\u003e6. \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Widerstrom M, Schonning C, Lilja M, Lebbad M, Ljung T, Allestam G,\u003cem\u003e\u0026nbsp;\u003c/em\u003eet al. Large outbreak of \u003cem\u003eCryptosporidium hominis\u003c/em\u003e infection transmitted through the public water supply, Sweden. Emerg Infect Dis\u003cem\u003e.\u0026nbsp;\u003c/em\u003e2014;20:581-89.\u003c/p\u003e\n\u003cp\u003e7. \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Caccio SM, Chalmers RM: Human cryptosporidiosis in Europe. Clin Microbiol Infect.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2016;22:471-80.\u003c/p\u003e\n\u003cp\u003e8. \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Hunter PR, Hughes S, Woodhouse S, Raj N, Syed Q, Chalmers RM, et al. Health sequelae of human cryptosporidiosis in immunocompetent patients. Clin Infect Dis.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2004;39:504-10.\u003c/p\u003e\n\u003cp\u003e9. \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Carter BL, Stiff RE, Elwin K, Hutchings HA, Mason BW, Davies AP, et al. Health sequelae of human cryptosporidiosis-a 12-month prospective follow-up study. Eur J Clin Microbiol Infect Dis.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2019; 38:1709-17.\u003c/p\u003e\n\u003cp\u003e10. \u0026nbsp; \u0026nbsp; \u0026nbsp; Igloi Z, Mughini-Gras L, Nic Lochlainn L, Barrasa A, Sane J, Mooij S, et al. Long-term sequelae of sporadic cryptosporidiosis: a follow-up study. Eur J Clin Microbiol Infect Dis.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2018;37:1377-84.\u003c/p\u003e\n\u003cp\u003e11. \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Carter B, Chalmers R, Davies A. Health sequelae of human cryptosporidiosis in industrialised countries: a systematic review. Parasites \u0026amp; Vectors. 2020;13:443.\u003c/p\u003e\n\u003cp\u003e12. \u0026nbsp; \u0026nbsp; \u0026nbsp; Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al.The \u0026nbsp; Burden of Cryptosporidium diarrheal disease among children \u0026lt; 24 months of age in moderate/high mortality regions of subSaharan Africa and south Asia, utilizing data from the global enteric multicenter study (GEMS). PLoS Negl Trop Dis. 2016;10: e0004729.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e13. \u0026nbsp; \u0026nbsp; \u0026nbsp; Guerrant DI, Moore SR, Lima AAM, Patrick PD, Schorling JB, Guerrant RL. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven years later in a poor urban community in northeast Brazil. Am J Trop Med Hyg\u003cem\u003e.\u0026nbsp;\u003c/em\u003e1999;61:707-13.\u003c/p\u003e\n\u003cp\u003e14. \u0026nbsp; \u0026nbsp; \u0026nbsp; Lilja M, Widerstrom M, Lindh J. Persisting post-infection symptoms 2 years after a large waterborne outbreak of \u003cem\u003eCryptosporidium hominis\u003c/em\u003e in northern Sweden. BMC Res Notes.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2018;11:625.\u003c/p\u003e\n\u003cp\u003e15. \u0026nbsp; \u0026nbsp; \u0026nbsp; Berkman DS, Lescano AG, Gilman RH, Lopez SL, Black MM. Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. Lancet.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2002;359:564-71.\u003c/p\u003e\n\u003cp\u003e16. \u0026nbsp; \u0026nbsp; \u0026nbsp; Rehn M, Wallensten A, Widerstrom M, Lilja M, Grunewald M, Stenmark S, et al. Post-infection symptoms following two large waterborne outbreaks of \u003cem\u003eCryptosporidium hominis\u003c/em\u003e in Northern Sweden, 2010-2011. BMC Public Health.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2015;15:529.\u003c/p\u003e\n\u003cp\u003e17. \u0026nbsp; \u0026nbsp; \u0026nbsp; Insulander M, Silverl\u0026aring;s C, Lebbad M, Karlsson L. Mattsson JG, Svenungsson B. Molecular epidemiology and clinical manifestations of human cryptosporidiosis in Sweden. Epidemiol Infect.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2013;141:1009-20.\u003c/p\u003e\n\u003cp\u003e18. \u0026nbsp; \u0026nbsp; \u0026nbsp; Litleskare S, Rortveit G, Eide GE, Hanevik K, Langeland N, Wensaas KA. Prevalence of irritable bowel syndrome and chronic fatigue 10 years after Giardia infection. Clin Gastroenterol Hepatol.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2018;16:1064-72.\u003c/p\u003e\n\u003cp\u003e19. \u0026nbsp; \u0026nbsp; \u0026nbsp; Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther.\u003cem\u003e\u0026nbsp;\u003c/em\u003e2007;26:535-44.\u003c/p\u003e\n\u003cp\u003e20. \u0026nbsp; \u0026nbsp; \u0026nbsp;Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1:133-46.\u003c/p\u003e\n\u003cp\u003e21. \u0026nbsp; \u0026nbsp; \u0026nbsp; Palsson OS, Whitehead WE, van Tilburg MA, Chang L, Chey W, Crowell\u0026nbsp; MD, et al. Rome IV Diagnostic questionnaires and tables for investigators and clinicians. Gastroenterology. 2016;150:1481-91.\u0026nbsp;\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-research-notes","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"resn","sideBox":"Learn more about [BMC Research Notes](http://bmcresnotes.biomedcentral.com)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/resn/default.aspx","title":"BMC Research Notes","twitterHandle":"@BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Cryptosporidium, sequelae, diarrhea, post-infectious symptoms ","lastPublishedDoi":"10.21203/rs.3.rs-742939/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-742939/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eObjectives\u003c/strong\u003e\u003c/p\u003e\u003cp\u003eIn 2010-2011, a waterborne outbreak of the parasite, \u003cem\u003eCryptosporidium hominis\u003c/em\u003e, affected approximately 27,000 inhabitants in the city of Östersund, Sweden. Previous research suggested that post-infectious symptoms, such as gastrointestinal symptoms and joint pain, could persist for up to two years after the initial infection. In this study, we investigated whether the parasite caused post-infectious sequelae for up to five years after the outbreak. This prospective cohort study examined whether individuals infected during the outbreak were more likely than uninfected individuals to report post-infectious symptoms five years later. The participants completed a questionnaire on whether they experienced a list of symptoms. We analysed data using logistic regression and calculated odds ratios with 95% confidence intervals.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eResults \u003c/strong\u003e\u003c/p\u003e\u003cp\u003eThe analysis included 626 individuals. Among the 262 individuals infected during the outbreak, 56.5% reported symptoms at follow-up. Compared to uninfected individuals, infected individuals were significantly more likely to report watery diarrhoea, diarrhoea, swollen joints, abdominal pain, bloating, joint discomfort, acid indigestion, alternating bowel habits, joint pain, ocular pain, nausea, and fatigue at the follow-up, after adjusting for age and sex. Our findings suggested that cryptosporidiosis was mainly associated with gastrointestinal- and joint-related post-infectious symptoms for up to 5 years after the infection.\u0026nbsp;\u003c/p\u003e","manuscriptTitle":"Outbreak of Cryptosporidium hominis in northern Sweden: persisting symptoms in a five-year follow-up","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2021-07-26 20:54:36","doi":"10.21203/rs.3.rs-742939/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Major revision","date":"2021-09-14T00:00:00+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2021-09-13T00:00:00+00:00","index":2,"fulltext":"Recommendation: Reviewer's comments unavailable due to the journal's policy.\n"},{"type":"reviewerAgreed","content":"","date":"2021-08-30T00:00:00+00:00","index":2,"fulltext":""},{"type":"editorInvitedReview","content":"","date":"2021-08-14T00:00:00+00:00","index":1,"fulltext":"Recommendation: Reviewer's comments unavailable due to the journal's policy.\n"},{"type":"reviewerAgreed","content":"","date":"2021-08-01T00:00:00+00:00","index":1,"fulltext":""},{"type":"reviewersInvited","content":"","date":"2021-07-17T00:00:00+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2021-07-12T00:00:00+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2021-07-11T23:00:00+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2021-07-11T23:00:00+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-research-notes","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"resn","sideBox":"Learn more about [BMC Research Notes](http://bmcresnotes.biomedcentral.com)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/resn/default.aspx","title":"BMC Research Notes","twitterHandle":"@BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"2469116e-58f9-4cfc-bb4d-24adc46caf07","owner":[],"postedDate":"July 26th, 2021","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[{"id":5980027,"name":"General Biochemistry"},{"id":5980028,"name":"Molecular Genetics"},{"id":5980029,"name":"Molecular Biology"}],"tags":[],"updatedAt":"2021-07-26T20:54:37+00:00","versionOfRecord":[],"versionCreatedAt":"2021-07-26 20:54:36","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-742939","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-742939","identity":"rs-742939","version":["v1"]},"buildId":"_2-kVJe1T_tPrBINL-cwx","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: preprint-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-05-26T02:00:01.498150+00:00
License: CC-BY-4.0